Background-The aetiology and pathophysiology of ulcerative colitis remains unclear; however, there is increasing recognition of the critical role of inflammatory cytokines in the pathogenesis of this disease. Among these, tumour necrosis factor a (TNFa) seems to play an important role. Aim-To study the effects of an engineered human monoclonal antibody to TNFa (CDP571) in the treatment of idiopathic ulcerative colitis in the cottontop tamarin. Methods-Six cottontop tamarins with confirmed ulcerative colitis received repeated doses of CDP571. Progression of disease was assessed by measuring both body weight and rectal biopsy pathology. Results-All animals showed a rapid improvement in clinical condition and rectal biopsy pathology that was maintained foliowing completion of the therapy. Conclusion-These studies indicate the efficacy of selective antibody therapy to TNFa for the treatment of ulcerative colitis in a primate and suggest that similar therapy in humans could be ofvalue. (Gut 1997; 40: 628-633) 
The term inflammatory bowel disease (IBD) encompasses two chronic disorders affecting all or part of the gastrointestinal tract. These are Crohn's disease and ulcerative colitis. For both diseases the causative agent is unclear. Proposed aetiologies include infectious agents,' 2response to measles vaccination,3 vascular disruptions,4 and disorders of the immune system. Furthermore, there is increasing evidence of a genetic susceptibility to these diseases, which may act alone or perhaps in association with environmental factors. 5 Ulcerative colitis and Crohn's disease both demonstrate characteristic clinicopathological features. A central feature is the local inflammatory response in the gut wall which is characterised by an influx of T-lymphocytes and other mononuclear cells, especially macrophages. 6 In recent years, numerous cytokines have been implicated as being crucial to the disease processes, including tumour necrosis factor ox (TNFot), interleukin (IL) 6, IL-1,,7 and platelet activating factor (PAF).8 However, the significance of individual cytokines has often been difficult to elucidate from clinical studies. At times, investigators have failed to show a consistent alteration in cytokine production or release in IBD. Furthermore, in patients receiving treatment, certain treatments -for example, 5-aminosalicylic acid or corticosteroids, or both, will cause a reduction in the concentrations of numerous cytokines in the colonic mucosa.9 More recently, the development of specific antibodies to cytokines such as TNFot has provided the opportunity to assess the possible roles of individual cytokines in the disease state both in animal models and in humans.
TNFot is a cytokine released by activated mononuclear cells and T cells. It seems to have a clinically important role in septic shock'0 and in rheumatoid arthritis. " In the latter condition selective blockade of TNFot by monoclonal antibodies will ameliorate the disease process.'2 In addition, TNFot has been implicated in the pathogenesis of IBD. Raised concentrations of TNFo have been noted in the serum'3 and increased TNFoL immunoreactivity has been shown in the lamina propria of patients with active Crohn's disease or ulcerative colitis.'4 Furthermore, it has been shown that there are significant increases in faecal TNFot concentrations in patients with active IBD. '5 A large number of animal models of IBD have been described and many have been reviewed previously. '6 In most cases the models are solely of colonic inflammation, not of IBD. Inflammation is often induced by the local application of an irritant, such as acetic acid, to the colon, in some cases with prior sensitisation of the animal to the irritant material. Although these approaches can be used to study various aspects of colonic inflammation, the resulting pathology shows few, if any, similarities to that seen in human IBD. Moreover, the pathological changes invariably improve once the insult has been removed, unlike the situation in humans. None the less, in a rodent model of colonic inflammation a beneficial response was noted after administration of a selective monoclonal antibody directed against TNFot. '7 The cottontop tamarin, a small, new world primate, is unique among animal models of IBD in that it develops a spontaneous form of colitis which shows many similarities to the condition of ulcerative colitis in humans.
Animals present clinically with chronic diarrhoea and weight loss and may die from the Overall maximum score 6 days 12, 32, 49, and 63. Biopsy specimens were evaluated by a pathologist using an objective scoring system developed from one used previously for assessing human rectal specimens (Table III) .26 Specimens were graded from 0 (normal) to 6 (severe active disease) on the basis of inflammatory cell infiltrate, crypt architecture and mucosal disruption (Fig 1) . Biopsy scores and body weights before and after CDP571 treatment were compared using the Friedman non-parametric repeated measures test. Differences were considered significant when p<0 05.
Blood samples were also taken when the animals were sedated for other proceduresthat is, on days 12, 25, 32,49, and 63, to permit measurement of plasma concentrations of CDP571 and of host antibodies to CDP57 1. 
ELISAS FOR CDP571 AND ANTIBODIES TO CDP571
ELISA techniques were used as described previously.27 Briefly, for the pharmacokinetic assay, diluted plasma samples were added to microtitre plates coated with rhTNFot and bound CDP571 was revealed with mouse antihuman IgG4 (Serotec) followed by horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG (Jacksons Laboratories). Bound HRP was revealed using TMB substrate and colour development as proportional to the amount of CDP571 in the sample.
Antibodies to CDP571 were detected using a double antigen sandwich ELISA system. Plasma samples (diluted 1 in 10 in phosphate buffered saline)/1% bovine serum albumin (BSA)) were added to CDP571 coated plates and the sandwich was completed with CDP571 conjugated to HRP, followed by TMB substrate. An affinity purified rabbit hyperimmune serum was used as a standard and results expressed as units/ml (1 unit being equivalent to 1 mg/ml of the rabbit standard). Figure 2 shows the plasma elimination profiles for the two animals. Analyses demonstrated that CDP571 was cleared from normal tamarins with a half-life of around six days (5 8 and 7-0 days). By day 28, there was little host antibody response to CDP57 1. Therefore, the drug was administered every six days in the therapeutic protocol.
Results

PHARMACOKINETIC STUDY
RESPONSE TO TREATMENT
None of the animals showed any adverse effects to repeated dosing with CDP57 1, either locally or systemically.
Analysis of plasma samples confirmed that during the treatment period, CDP571 concentrations continued to reach circulating levels in excess of 100 ,ug/ml (range 51A4-227-8 jLg/ml; Table IV ) and remained in circulation for several weeks (geometric mean of 0.5 Vg/ml and range of 0-05-6-5 ,ug/ml at day 49). No immune response to the antibody was detected during the treatment period, although low levels of antibodies to CDP571 (3-9 units/ml) were seen in four of the six animals when CDP571 was cleared from the circulation after the final dose.
All animals showed a clinical response to treatment and in all cases there was an improvement in faecal quality after starting treatment. Figure 3 shows changes in body weight. Mean body weight rose following the first dose of antibody and remained significantly elevated during the treatment period and during the following month (+33 3 (10) g (mean (SEM)) at day 63, p<005). This represents an increase of around 6% compared with pre-entry body weight and was maintained throughout the study.
Examination of rectal biopsy specimens showed a rapid fall in mean rectal biopsy score after starting treatment (Table V) , indicating a value of 4-5 (02) to 3 (0-4) (p<0 05). This u improvement was maintained until day 49.
Discussion
Recent advances in the understanding of the mechanisms and control of inflammation have j focused on the importance of numerous cyto-28 kines in this process. TNFot seems to play an important role in septic shock, rheumatoid arthritis and IBD. This has been demonstrated by the raised concentrations of TNFot both in plasma and locally in inflamed tissues in these conditions and has led to the development of monoclonal antibodies as potential therapies in these conditions. A murine antibody to TNFct tric has been used in early phase trials in patients with septic shock28 but was associated with a 5 significant host response to the antibody. However, antibody engineering involving either chimerisation or CDR grafting of murine monoclonal antibodies to TNFot to reduce immunogenicity has permitted certain conditions -for example, rheumatoid arthritis, to be treated.'2 29 From this background, we evaluated the use of an antibody to TNFax in the treatment of ulcerative colitis in an animal model. Previous work using chemically induced colonic inflammation in rats"7 has clearly demonstrated the ability of anti-murine TNFot to modulate the inflammatory response; however, the initial dose was given prior to the induction of inflammation. In ulcerative colitis in humans, treatment is required once disease is diagnosed and often the disease process may be longstanding before treatment is instituted. 
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